Evidence map›Paper›PMID 36838817›Full record

ArticleMolecules (Basel, Switzerland)2023

Development of Computational In Silico Model for Nano Lipid Carrier Formulation of Curcumin.

Omar Waleed Abduljaleel Albasri, Palanirajan Vijayaraj Kumar, Mogana Sundari Rajagopal

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Omar Waleed Abduljaleel AlbasriFaculty of Pharmaceutical Sciences, Department of Pharmaceutical Technology, UCSI University, Jalan Menara Gading, Taman Connaught, Cheras, Kuala Lumpur 56000, Malaysia.
Palanirajan Vijayaraj KumarFaculty of Pharmaceutical Sciences, Department of Pharmaceutical Technology, UCSI University, Jalan Menara Gading, Taman Connaught, Cheras, Kuala Lumpur 56000, Malaysia.ORCID 0000-0003-1129-7084
Mogana Sundari RajagopalFaculty of Pharmaceutical Sciences, Department of Pharmaceutical Technology, UCSI University, Jalan Menara Gading, Taman Connaught, Cheras, Kuala Lumpur 56000, Malaysia.ORCID 0000-0002-5664-9293

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oral delivery system is very important and plays a significant role in increasing the solubility of drugs, which eventually will increase their absorption by the digestive system and enhance the drug bioactivity. This study was conducted to synthesize a novel curcumin nano lipid carrier (NLC) and use it as a drug carrier with the help of computational molecular docking to investigate its solubility in different solid and liquid lipids to choose the optimum lipids candidate for the NLCs formulation and avoid the ordinary methods that consume more time, materials, cost, and efforts during laboratory experiments. The antiviral activity of the formed curcumin-NLC against SARS-CoV-2 (COVID-19) was assessed through a molecular docking study of curcumin's affinity towards the host cell receptors. The novel curcumin drug carrier was synthesized as NLC using a hot and high-pressure homogenization method. Twenty different compositions of the drug carrier (curcumin nano lipid) were synthesized and characterized using different physicochemical techniques such as UV-Vis, FTIR, DSC, XRD, particle size, the zeta potential, and AFM. The in vitro and ex vivo studies were also conducted to test the solubility and the permeability of the 20 curcumin-NLC formulations. The NLC as a drug carrier shows an enormous enhancement in the solubility and permeability of the drug.

Indexed as

COVID-19CurcuminNanostructuresDrug CarriersHumansLipidsMolecular Docking SimulationParticle SizeSARS-CoV-2CurcuminDrug CarriersLipidscurcumindrug carriermolecular dockingNLCspermeabilitySLNs

Identifiers

PMID36838817
PMCPMC9965590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.